Dihydropyridine-derived calcium channel blocker as a promising anti-hantavirus entry inhibitor.
Hantaan virus
antivirals
benidipine hydrochloride
bunyavirales
calcium channel blocker
hantavirus
hantavirus pulmonary syndrome
hemorrhagic fever with renal syndrome
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
05
2022
accepted:
25
07
2022
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
Hantaviruses, the causative agent for two types of hemorrhagic fevers, hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS), are distributed from Eurasia to America. HFRS and HPS have mortality rates of up to 15% or 45%, respectively. Currently, no certified therapeutic has been licensed to treat hantavirus infection. In this study, we discovered that benidipine hydrochloride, a calcium channel blocker, inhibits the entry of hantaviruses
Identifiants
pubmed: 36105208
doi: 10.3389/fphar.2022.940178
pii: 940178
pmc: PMC9465303
doi:
Types de publication
Journal Article
Langues
eng
Pagination
940178Informations de copyright
Copyright © 2022 Wang, Pei, Zhang, Li, Dang, Liu, Wang, Zhang, Qi, Yang, Cheng, Dong, Qian, Xu, Lei, Zhang and Ye.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Viruses. 2019 Jul 04;11(7):
pubmed: 31277410
Biochem Biophys Res Commun. 2020 Jun 18;527(1):297-304
pubmed: 32446384
Cell. 2020 Oct 15;183(2):442-456.e16
pubmed: 32937107
Nat Rev Microbiol. 2013 Aug;11(8):539-50
pubmed: 24020072
Viruses. 2020 Jun 30;12(7):
pubmed: 32629804
Sci Transl Med. 2015 Jun 3;7(290):290ra89
pubmed: 26041706
Mol Cell. 2017 Jun 15;66(6):780-788
pubmed: 28622523
Front Microbiol. 2018 Dec 05;9:2954
pubmed: 30568638
Br J Pharmacol. 1990 Aug;100(4):669-76
pubmed: 2169935
J Pharm Pharmacol. 2000 May;52(5):561-8
pubmed: 10864145
Adv Virus Res. 2019;104:185-224
pubmed: 31439149
Front Microbiol. 2020 Jun 12;11:1105
pubmed: 32595613
Viruses. 2021 Apr 16;13(4):
pubmed: 33923413
Pathogens. 2020 Sep 22;9(9):
pubmed: 32971887
Clin Exp Pharmacol Physiol. 2020 Sep 7;:
pubmed: 32894790
Curr Opin Virol. 2021 Oct;50:87-94
pubmed: 34418649
Viruses. 2014 Apr 21;6(4):1801-22
pubmed: 24755564
Clin Microbiol Rev. 2010 Apr;23(2):412-41
pubmed: 20375360
Infect Genet Evol. 2015 Jan;29:146-55
pubmed: 25461845
Cell Discov. 2020 Mar 16;6:14
pubmed: 32194980
J Infect Dis. 2018 Nov 22;218(suppl_5):S588-S591
pubmed: 29982632
Virol Sin. 2017 Feb;32(1):32-43
pubmed: 28120221
J Pharmacol Sci. 2006 Apr;100(4):243-61
pubmed: 16565579
Cell Host Microbe. 2016 Aug 10;20(2):259-70
pubmed: 27476412
Sci Transl Med. 2013 Sep 25;5(204):204ra131
pubmed: 24068738
J Virol. 2010 Sep;84(17):8721-31
pubmed: 20538858
Front Pharmacol. 2019 Oct 16;10:1203
pubmed: 31680975
Science. 2015 Feb 27;347(6225):995-8
pubmed: 25722412
Atherosclerosis. 2005 Jan;178(1):57-66
pubmed: 15585201
Front Cell Infect Microbiol. 2020 Aug 04;10:399
pubmed: 32903721
Cell Res. 2019 Sep;29(9):739-753
pubmed: 31444469
Jpn J Pharmacol. 1990 Apr;52(4):553-62
pubmed: 2342226
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573
Front Cell Infect Microbiol. 2016 Dec 20;6:185
pubmed: 28066721